Company / Operating Cash Flow
ANI Pharmaceuticals, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$185.2M
FY2025
5-year range
-$31.2M / $185.2M
FY2021-FY2025
Trend
+189.3%
vs FY2024
Sector context
#41 of 216
Health Care
What the data says
ANI Pharmaceuticals, Inc.'s operating cash flow of $185M is higher than 81% of companies in the Health Care sector (FY2025). Operating Cash Flow has fluctuated over the past 10 years, ranging from -$31M in FY2022 to $185M in FY2025.
Based on SEC 10-K filings.
$185M in FY2025 with a 5-year CAGR of +64.7%. Top quartile in the Health Care sector.
Improved from $119M to $185M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +64.7%
- 10-Year CAGR
- -
Sector benchmark
-71.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +64.7%, indicating consistent growth.
- In FY2025, operating cash flow increased 189.3% year-over-year.
- Ranks #41 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $185.2M | +189.3% |
| FY2024 | $64.0M | -46.2% |
| FY2023 | $119.0M | +481.2% |
| FY2022 | -$31.2M | -1039.3% |
| FY2021 | $3.3M | -78.2% |
| FY2020 | $15.3M | -66.5% |
| FY2019 | $45.6M | -32.0% |
| FY2018 | $67.1M | +70.2% |
| FY2017 | $39.4M | +43.5% |
| FY2016 | $27.5M | +600.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026